KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Equity Average (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Equity Average for 8 consecutive years, with $469.0 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 4.57% to $469.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $469.0 million through Dec 2025, up 4.57% year-over-year, with the annual reading at $463.4 million for FY2025, 9.4% up from the prior year.
  • Equity Average hit $469.0 million in Q4 2025 for Castle Biosciences, up from $461.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $469.0 million in Q4 2025 to a low of $382.0 million in Q2 2023.
  • Historically, Equity Average has averaged $417.9 million across 5 years, with a median of $413.5 million in 2021.
  • Biggest five-year swings in Equity Average: surged 382.12% in 2021 and later decreased 8.23% in 2023.
  • Year by year, Equity Average stood at $411.7 million in 2021, then dropped by 1.56% to $405.3 million in 2022, then fell by 4.14% to $388.5 million in 2023, then grew by 15.42% to $448.4 million in 2024, then rose by 4.57% to $469.0 million in 2025.
  • Business Quant data shows Equity Average for CSTL at $469.0 million in Q4 2025, $461.2 million in Q3 2025, and $447.8 million in Q2 2025.